Apr. 24 at 1:03 AM
$MRNA Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
The presentation details are as follows:
Oral Presentation:
Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study Session Type/Title: Oral Abstract Session - Melanoma/Skin Cancers Data & Time: June 1, 8:00 AM - 11:00 AM CT Presenter: Matteo S. Carlino, MBBS, PhD, FRACP
Poster Presentations:
Abstract #9564: Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma Session Type/Title: Poster Session - Melanoma/Skin Cancers: Poster Board #280 Date & Time: May 31, 9:00 AM - 12:00 PM CDT Presenter: Ryan J. Sullivan, MD
Abstract #TPS7580: A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma Session Type/Title: Poster Session - Hematologic Malignancies - Plasma Cell Dyscrasia: Poster Board #457b Date & Time: June 1, 9:00 AM -